VentrilinksCreate a diligence case, refine the thesis live with the AI agent, and export
an evidence-backed report or investment memo with key claims traced to dated sources.
Set up your case to begin
Biotech decision-makers use VentriLinks for
Built from millions of conference abstracts, publications, trial records, and curated databases,
the Agent connects companies, assets, targets, indications, trials, mechanisms, and development stages
into a source-traced knowledge foundation for biotech diligence.
01 / 07
Every approved, clinical, investigational, and preclinical compound — carrying ChEMBL, DrugBank, PubChem, RxNorm, UNII, CAS, and InChIKey identifiers.
02 / 07
Gene and protein targets with druggability, genetic association, and expression — over 1.4M target mentions mined from the literature and trials.
03 / 07
Trials and readouts from every registry worldwide — 205,175 linked to a drug asset, in pursuit of the 100% coverage mandate.
04 / 07
First-class disease entities with ontology IDs, epidemiology, and unmet-need fields — 228,568 target↔indication validation edges.
05 / 07
The corpus that surfaces preclinical and academic competitors before they incorporate — plus 534,109 authors and PIs across 751,755 authorship links.
06 / 07
Sponsors, financials, and deals — 242,029 trial sponsorships and 120,681 collaboration edges, classified commercial vs. academic at ingestion.
07 / 07
Every fact above traces here — 4,037,721 EVIDENCED_BY links binding each claim to a dated source artifact with type, URL, and supporting span.
Proven results
Competing programs surfaced
across every global registry, patent office, and preprint server
100%
Median time to a first-draft memo
down from roughly three weeks of analyst work
4 hrs
Entities in the knowledge graph
drugs, targets, trials, companies, and evidence
1.6M+
Evidence artifacts behind every claim
each fact dated and traced to its source
1.3M+
Reduce diligence cost per deal
more theses evaluated per analyst, per week
>80%